Plain-English translation of NCT06575296 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new medication called as a maintenance therapy for patients who have received a stem cell transplant for acute leukemia with specific genetic mutations (NPM1 or KMT2A changes). The medication is taken by mouth once or twice daily for up to two years after your transplant. This is a Phase 1 trial, which means researchers are first studying whether the medication is safe and finding the right dose before testing it more broadly.
After a stem cell transplant, leukemia can sometimes return, even when the initial treatment was successful. This trial exists to see whether taking this medication after transplant can help keep the disease from coming back and improve long-term survival for patients with these particular types of leukemia.
You likely qualify if…
You likely don't qualify if…
You would start taking the new medication by mouth once or twice daily, beginning 50 to 150 days after your stem cell transplant. You would take it for 28 days, then have a break, and repeat this cycle for up to 2 years. During the trial, you would have regular study visits that include blood tests, bone marrow samples, and heart imaging when needed. Researchers will closely monitor you for any side effects and check whether your leukemia is staying under control.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States